A clinical trial of in vitro-expanded naïve Tregs is also underway in Crohn’s Disease, the first application of FOXP3+ Treg immunotherapy for inflammatory bowel disease (IBD) (ISRCTN97547683) (29). Here, FOXP3 is linked to inflammatory bowel disease.